C P Chung1, M J Ormseth2, M A Connelly3, A Oeser2, J F Solus2, J D Otvos3, P Raggi4, C M Stein2. 1. Department of Medicine, Vanderbilt University, Nashville, USA c.chung@vanderbilt.edu. 2. Department of Medicine, Vanderbilt University, Nashville, USA. 3. LabCorp, Raleigh, USA. 4. Department of Medicine, University of Alberta, Edmonton, Canada.
Abstract
BACKGROUND: GlycA is a novel marker of systemic inflammation detected by nuclear magnetic resonance (NMR) spectroscopy. In the general population, GlycA is correlated with inflammatory markers such as C-reactive protein (CRP) and associated with coronary heart disease and diabetes. The utility of GlycA in patients with systemic lupus erythematosus (SLE) has not been defined. Therefore, we tested the hypothesis that GlycA concentrations are elevated in patients with SLE and associated with other markers of inflammation and coronary atherosclerosis. METHODS: We compared concentrations of GlycA, detected by NMR, in 116 patients with SLE and 84 control subjects frequency-matched for age, sex, and race. SLE disease activity index (SLEDAI) and the SLE Collaborating Clinics damage index (SLICC) were calculated. Acute phase reactants, a panel of cytokines, and a lipid panel were measured. Electron beam computer tomography (EBCT) was used to quantify coronary artery calcification, a measure of coronary artery atherosclerosis. RESULTS: Patients with SLE had higher concentrations of GlycA (398 (350-445)) than control subjects (339 (299-391)) µmol/L, p < 0.001. In patients with SLE, concentrations of GlycA were significantly associated with sedimentation rate (rho = 0.43), C-reactive protein (rho = 0.59), e-selectin (rho = 0.28), intracellular adhesion molecule-1 (rho = 0.30), triglycerides (rho = 0.45), all p < 0.0023 to account for multiple comparisons, but not with creatinine, SLEDAI, SLICC, or coronary calcium scores. CONCLUSIONS: Concentrations of GlycA are higher in patients with SLE than control subjects and associated with markers of inflammation but not with SLE disease activity or chronicity scores or coronary artery calcification.
BACKGROUND:GlycA is a novel marker of systemic inflammation detected by nuclear magnetic resonance (NMR) spectroscopy. In the general population, GlycA is correlated with inflammatory markers such as C-reactive protein (CRP) and associated with coronary heart disease and diabetes. The utility of GlycA in patients with systemic lupus erythematosus (SLE) has not been defined. Therefore, we tested the hypothesis that GlycA concentrations are elevated in patients with SLE and associated with other markers of inflammation and coronary atherosclerosis. METHODS: We compared concentrations of GlycA, detected by NMR, in 116 patients with SLE and 84 control subjects frequency-matched for age, sex, and race. SLE disease activity index (SLEDAI) and the SLE Collaborating Clinics damage index (SLICC) were calculated. Acute phase reactants, a panel of cytokines, and a lipid panel were measured. Electron beam computer tomography (EBCT) was used to quantify coronary artery calcification, a measure of coronary artery atherosclerosis. RESULTS:Patients with SLE had higher concentrations of GlycA (398 (350-445)) than control subjects (339 (299-391)) µmol/L, p < 0.001. In patients with SLE, concentrations of GlycA were significantly associated with sedimentation rate (rho = 0.43), C-reactive protein (rho = 0.59), e-selectin (rho = 0.28), intracellular adhesion molecule-1 (rho = 0.30), triglycerides (rho = 0.45), all p < 0.0023 to account for multiple comparisons, but not with creatinine, SLEDAI, SLICC, or coronary calcium scores. CONCLUSIONS: Concentrations of GlycA are higher in patients with SLE than control subjects and associated with markers of inflammation but not with SLE disease activity or chronicity scores or coronary artery calcification.
Authors: Luis M Vilá; Graciela S Alarcón; Gerald McGwin; Holly M Bastian; Barri J Fessler; John D Reveille Journal: J Rheumatol Date: 2005-11 Impact factor: 4.666
Authors: Yu Asanuma; Annette Oeser; Ayumi K Shintani; Elizabeth Turner; Nancy Olsen; Sergio Fazio; MacRae F Linton; Paolo Raggi; C Michael Stein Journal: N Engl J Med Date: 2003-12-18 Impact factor: 91.245
Authors: Rossini Botev; Jean-Pierre Mallié; Cecilé Couchoud; Otto Schück; Jean-Pierre Fauvel; Jack F M Wetzels; Nelson Lee; Natale G De Santo; Massimo Cirillo Journal: Clin J Am Soc Nephrol Date: 2009-04-30 Impact factor: 8.237
Authors: Cecilia P Chung; Annette Oeser; Paolo Raggi; Joseph F Solus; Ingrid Avalos; MacRae F Linton; Sergio Fazio; C Michael Stein Journal: Clin Rheumatol Date: 2008-04-18 Impact factor: 2.980
Authors: Yu Asanuma; Cecilia P Chung; Annette Oeser; Ayumi Shintani; Eran Stanley; Paolo Raggi; C Michael Stein Journal: J Rheumatol Date: 2006-02-01 Impact factor: 4.666
Authors: D Gladman; E Ginzler; C Goldsmith; P Fortin; M Liang; M Urowitz; P Bacon; S Bombardieri; J Hanly; E Hay; D Isenberg; J Jones; K Kalunian; P Maddison; O Nived; M Petri; M Richter; J Sanchez-Guerrero; M Snaith; G Sturfelt; D Symmons; A Zoma Journal: Arthritis Rheum Date: 1996-03
Authors: Aditya A Joshi; Joseph B Lerman; Tsion M Aberra; Mehdi Afshar; Heather L Teague; Justin A Rodante; Parasuram Krishnamoorthy; Qimin Ng; Tarek Z Aridi; Taufiq Salahuddin; Balaji Natarajan; Benjamin N Lockshin; Mark A Ahlman; Marcus Y Chen; Daniel J Rader; Muredach P Reilly; Alan T Remaley; David A Bluemke; Martin P Playford; Joel M Gelfand; Nehal N Mehta Journal: Circ Res Date: 2016-09-21 Impact factor: 17.367
Authors: Stewart J Wiseman; Mark E Bastin; Charlotte L Jardine; Gayle Barclay; Iona F Hamilton; Elaine Sandeman; David Hunt; E Nicole Amft; Susan Thomson; Jill F F Belch; Stuart H Ralston; Joanna M Wardlaw Journal: Stroke Date: 2016-10-04 Impact factor: 7.914
Authors: Margery A Connelly; Chisato Shimizu; Deborah A Winegar; Irina Shalaurova; Ray Pourfarzib; James D Otvos; John T Kanegaye; Adriana H Tremoulet; Jane C Burns Journal: BMC Pediatr Date: 2016-09-05 Impact factor: 2.125
Authors: Paulette D Chandler; Akintunde O Akinkuolie; Deirdre K Tobias; Patrick R Lawler; Chungying Li; M Vinayaga Moorthy; Lu Wang; Daniel A Duprez; David R Jacobs; Robert J Glynn; James Otvos; Margery A Connelly; Wendy S Post; Paul M Ridker; JoAnn E Manson; Julie E Buring; I-Min Lee; Samia Mora Journal: PLoS One Date: 2016-11-30 Impact factor: 3.240
Authors: David B Bartlett; Cris A Slentz; Margery A Connelly; Lucy W Piner; Leslie H Willis; Lori A Bateman; Esther O Granville; Connie W Bales; Kim M Huffman; William E Kraus Journal: Oxid Med Cell Longev Date: 2017-05-31 Impact factor: 6.543
Authors: David B Bartlett; Margery A Connelly; Hiba AbouAssi; Lori A Bateman; K Noelle Tune; Janet L Huebner; Virginia B Kraus; Deborah A Winegar; James D Otvos; William E Kraus; Kim M Huffman Journal: Arthritis Res Ther Date: 2016-04-12 Impact factor: 5.156
Authors: Margery A Connelly; James D Otvos; Irina Shalaurova; Martin P Playford; Nehal N Mehta Journal: J Transl Med Date: 2017-10-27 Impact factor: 5.531